Christopher Ogden

CIK: 0001914523

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (45.5%)

Position reduction

Option Exercises (M)1 (9.1%)

Derivative conversions

Awards (A)5 (45.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CTMX

CytomX Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

CTMX
CytomX Therapeutics, Inc.
Jun 15, 2026
Sale(S)
Direct
1.6K shares at avg. $3.05$5K
CTMX
CytomX Therapeutics, Inc.
Mar 17, 2026
Sale(S)
Direct
19.3K shares at avg. $6.42$124K
CTMX
CytomX Therapeutics, Inc.
Feb 2, 2026
Award(A)
Direct
90K shares-
CTMX
CytomX Therapeutics, Inc.
Sep 26, 2025
Award(A)
Stock Option (Right to Buy)
Direct
78.3K shares-
CTMX
CytomX Therapeutics, Inc.
Sep 26, 2025
Award(A)
Performance Stock Units (PSUs)
Direct
39.2K shares-
CTMX
CytomX Therapeutics, Inc.
Jun 16, 2025
Sale(S)
Direct
10.6K shares at avg. $2.69$29K
CTMX
CytomX Therapeutics, Inc.
Jun 13, 2025
Exercise(M)
Direct
37.5K shares-
CTMX
CytomX Therapeutics, Inc.
Jun 13, 2025
Sale(S)
Direct
1.6K shares at avg. $2.95$5K
CTMX
CytomX Therapeutics, Inc.
Mar 18, 2025
Sale(S)
Direct
8.6K shares at avg. $0.60$5K
CTMX
CytomX Therapeutics, Inc.
Feb 4, 2025
Award(A)
Direct
57.5K shares-
CTMX
CytomX Therapeutics, Inc.
Feb 4, 2025
Award(A)
Direct
44K shares-

		Type	Shares	Price		Ownership
Jun 15, 2026	CTMX CytomX Therapeutics, Inc.	Sale(S)	1,624	$3.05	$4,953	Direct
Mar 17, 2026	CTMX CytomX Therapeutics, Inc.	Sale(S)	19,323	$6.42	$124,112	Direct
Feb 2, 2026	CTMX CytomX Therapeutics, Inc.	Award(A)	90,000	-	$0	Direct
Sep 26, 2025	CTMX CytomX Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	78,250	-	-	Direct
Sep 26, 2025	CTMX CytomX Therapeutics, Inc.	Award(A) Performance Stock Units (PSUs)	39,150	-	-	Direct
Jun 16, 2025	CTMX CytomX Therapeutics, Inc.	Sale(S)	10,614	$2.69	$28,540	Direct
Jun 13, 2025	CTMX CytomX Therapeutics, Inc.	Exercise(M)	37,500	-	-	Direct
Jun 13, 2025	CTMX CytomX Therapeutics, Inc.	Sale(S)	1,641	$2.95	$4,841	Direct
Mar 18, 2025	CTMX CytomX Therapeutics, Inc.	Sale(S)	8,551	$0.60	$5,122	Direct
Feb 4, 2025	CTMX CytomX Therapeutics, Inc.	Award(A)	57,500	-	-	Direct
Feb 4, 2025	CTMX CytomX Therapeutics, Inc.	Award(A)	44,000	-	-	Direct

1-11 of 11 transactions

About Ogden Christopher

Ogden Christopher (SEC CIK 0001914523) files insider reports with the SEC as Chief Financial Officer of CytomX Therapeutics, Inc. (CTMX).

Signal8 holds 7 ownership filings by Ogden Christopher, all Form 4s, filed between Feb 6, 2025 and Jun 17, 2026. Those filings report 11 transactions, from Feb 4, 2025 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ogden Christopher's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Ogden Christopher

Jun 15, 2026: Open-market sale of CTMX shares (Form 4, code S).
Mar 17, 2026: Open-market sale of CTMX shares (Form 4, code S).
Feb 2, 2026: Grant or award of CTMX shares (Form 4, code A).
Sep 26, 2025: Grants or awards of CTMX derivative securities (2 lines, Form 4, code A).
Jun 16, 2025: Open-market sale of CTMX shares (Form 4, code S).

Other insiders filing for CytomX Therapeutics, Inc. (CTMX)

McCarthy Sean A., CEO
Carvajal Alejandra, Chief Legal Officer
Fuchs Charles S., Director
Su Zhen, Director
Young Matthew P., Director
Mohindru Mani, Director

How to read Form 4 transaction codes